Jeff Hall

In a study of over 1.300 women with dense breasts, the combination of mammography and ultrasound had a recall rate of 11.7 percent, a specificity rate of 89.1 percent and an accuracy rate of 89.2 percent in comparison to a 21.4 percent recall rate, 79.4 percent specificity and 79.5 percent accuracy for the combination of mammography, ultrasound, and artificial intelligence (AI).

Indicated for use in two-dimensional transthoracic echocardiography (2D-TTE) in adults, the AI Guidance software reportedly enables novice ultrasound users to obtain real-time cardiac imaging at the point of care.

In a study of 601 patients with prostate cancer, researchers found that only one patient with extensive metastasis was falsely diagnosed as non-metastatic on whole-body, low-dose computed tomography (CT) by reviewing radiologists.

In a dataset enriched for African American women, BRCA mutation carriers and those with benign breast disease, a mammography-based deep learning model demonstrated a five-year AUC of 63 percent for predicting breast cancer in comparison to 54 percent for BI-RADS assessment.

In a study of over 20,700 people, researchers found that artificial intelligence (AI) analysis of body composition measurements via lung cancer screening computed tomography (CT) exams improves the prediction of mortality risks for lung cancer, cardiovascular disease, and all-cause mortality.

A newly published review of 29 prospective studies revealed the use of MRI-guided daily adaptive SBRT in the management of prostate cancer was associated with significantly lower risks of acute grade 2 or higher genitourinary (GU) and gastrointestinal (GI) toxicities in comparison to CT-guided non-adaptive SBRT.

The newly FDA-cleared Fibroid Mapping Reviewer Application, which allows the creation of 3D uterus models from ultrasound images, reportedly facilitates diagnosis and interventional procedures for patients with uterine fibroids.

In a study of nearly 2,500 patients with incidental pulmonary nodules (IPN) on chest computed tomography (CT) exams, 69.5 percent of those in the highest quartile of the CDC’s Social Vulnerability Index (SVI) had inappropriate IPN follow-up in comparison to 54.3 percent of those in the lowest quartile of the CDC SVI.

In a video interview, Jacob Dubroff, M.D., Ph.D., discussed the potential impact of the recent CMS proposal to rein in Medicare coverage restrictions on the use of amyloid positron emission tomography (PET) for patients with Alzheimer’s disease.

Newly published research suggests the use of gadopiclenol at 0.05 mmol/kg is non-inferior to gadobutrol 0.1 mmol/kg for all qualitative visualization parameters on full-body magnetic resonance imaging (MRI).

An artificial intelligence model, trained on MRI and FLAIR imaging from over 900 patients with multiple sclerosis, demonstrated a 96 percent accuracy rate and 99 percent specificity rate for contrast-enhancing lesions in this patient population.

Recognizing the advent of beta amyloid-targeted therapies for the treatment of Alzheimer’s disease, the Centers for Medicare and Medicaid (CMS) has proposed eliminating coverage restrictions that limit amyloid positron emission tomography (PET) scans to clinical trial participants and one amyloid PET scan per lifetime.

In a recent interview at the SNMMI conference, Roger Lecomte, Ph.D., and Vincent Doyon discussed the advent of ultra-high resolution (UHR) brain positron emission tomography (PET), which reportedly offers double the spatial resolution of conventional PET and may facilitate earlier detection of Alzheimer’s disease and other conditions.

Optimized for musculoskeletal assessment, needle guidance and vascular access, the PocketPro H2 wireless ultrasound unit reportedly provides 90 minutes of high-quality continuous scanning for point-of-care applications.

Examining the use of the Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA) PET/CT (RECIP 1.0) model for assessing the treatment of metastatic castration-resistant prostate cancer, researchers found robust agreement between quantitative application of RECIP via tumor segmentation software and qualitative application of the model through reads by nuclear medicine physicians.

For conditions ranging from interstitial lung disease and post-COVID-19 complications to idiopathic pulmonary fibrosis, photon-counting computed tomography (PCCT) facilitates simultaneous functional and morphologic lung assessment at lower radiation dosing than conventional chest CT, according to newly published research.

In a retrospective review of over 110 million imaging claims for patients with commercial insurance or Medicare Advantage, researchers noted key trends signaling significant increases in imaging billed by non-physician practitioners (NPPs).

Patients with extraprostatic extension (EPE) on pre-prostatectomy MRI had a 3.6-fold higher risk for biochemical recurrence (BCR) of prostate cancer and a 25 percent lower three-year BCR-free survival rate in comparison to patients without EPE on pre-op MRI, according to newly published research.

In a recent interview at the SNMMI conference, Krishna Patel, M.D., discussed the benefits of the PET perfusion radiotracer agent 18F-flurpiridaz and new research findings showing the agent’s increased sensitivity and specificity in diagnosing coronary artery disease in obese patients.

An artificial intelligence (AI)-enabled platform that can reportedly diagnose heart failure with preserved ejection fraction (HFpEF) through analysis of a single echocardiogram view, the EchoGo Heart Failure now has a HCPCS code for use of the technology in outpatient settings for Medicare beneficiaries.

The use of single-photon emission computed tomography (SPECT)/computed tomography (CT) to monitor the effectiveness of Lu-177-PSMA (Pluvicto) in treating prostate cancer led to a greater than 50 percent decrease in prostate-specific antigen (PSA) level for 60 percent of patients in a new study, noted Andrew Nguyen, MBBS, FRACP, AANMS, in a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.

The prospective multicenter trial, which is slated to begin patient recruitment in late 2023, will reportedly assess the ability of 64Cu SAR-bisPSMA to diagnose prostate cancer within pelvic lymph nodes.

Reportedly receiving the first Current Procedural Terminology (CPT) III code from the American Medical Association (AMA) for artificial intelligence (AI)-enabled brain magnetic resonance imaging (MRI) software, Icometrix says its adjunctive quantification software can be utilized for diagnosis and assessment of conditions ranging from Alzheimer’s disease and epilepsy to stroke and dementia.

New research suggests the use of high-pitch photon-counting computed tomography (PCCT) facilitates similar image quality and attenuation in the pulmonary trunk at lower iodinated contrast media (ICM) dosing levels ranging from 35 to 60 ml.

Employing a hybrid positron emission tomography (PET)/magnetic resonance imaging (MRI) model to assess predictive features of Alzheimer’s disease (AD), researchers noted a 100 percent sensitivity rate and a 93 percent sensitivity rate for distinguishing between AD and normal cognition, according to a study presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.

In an interview at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Jeremie Calais, M.D., MSc discussed promising research findings for the use of the positron emission tomography (PET) imaging agent 89ZR-DFO-girentuximab for diagnosing clear cell renal cell carcinoma.

New research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference suggests that neuroreceptor differences in reactions to visual food cues between obese people and normal-weight individuals may improve the understanding of underlying mechanisms that contribute to obesity.

In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D., Ph.D, F.A.C.R., discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.

The artificial intelligence (AI) software facilitates high-resolution three-dimensional computed tomography (CT) images of the breast.

A next-generation positron emission tomography/computed tomography (PET/CT) system, Biograph Vision.X, reportedly offers enhanced spatial resolution and a time of flight of 178 picoseconds.